202 results on '"Albigès L"'
Search Results
2. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial
3. Renal cell carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
4. Nivolumab in patients with advanced renal cell carcinoma in France: interim results of the observational, real-world WITNESS study
5. Gastrointestinal metastases in renal cell carcinoma: A retrospective multicenter GETUG (Groupe d′Étude des Tumeurs Uro-Génitales) study
6. The role of radiation therapy for de novo metastatic bladder and renal cancers
7. Avelumab + axitinib versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma: final analysis of the phase III JAVELIN Renal 101 trial
8. Efficacy of avelumab plus axitinib versus sunitinib by numbers of IMDC risk factors and target tumor sites at baseline in advanced renal cell carcinoma: long-term follow-up results from JAVELIN Renal 101
9. Extended follow-up from JAVELIN Renal 101: subgroup analysis of avelumab plus axitinib versus sunitinib by the International Metastatic Renal Cell Carcinoma Database Consortium risk group in patients with advanced renal cell carcinoma
10. Circulating Biomarkers in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma Treated With Everolimus in the Pre-nephrectomy Setting
11. French AFU Cancer Committee Guidelines - Update 2022-2024: management of kidney cancer
12. Tratamiento del cáncer de riñón metastásico
13. Efficacy and safety of avelumab plus axitinib in elderly patients with advanced renal cell carcinoma: extended follow-up results from JAVELIN Renal 101
14. Association of cabozantinib pharmacokinetics, progression and toxicity in metastatic renal cell carcinoma patients: results from a pharmacokinetics/pharmacodynamics study
15. ESMO Clinical Practice Guideline update on the use of immunotherapy in early stage and advanced renal cell carcinoma
16. Checkpoint inhibitors in metastatic papillary renal cell carcinoma
17. Efficacy and correlative analyses of avelumab plus axitinib versus sunitinib in sarcomatoid renal cell carcinoma: post hoc analysis of a randomized clinical trial
18. Recommandations françaises du Comité de cancérologie de l’AFU – actualisation 2020–2022 : prise en charge du cancer du rein
19. Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus
20. Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma
21. Prognosis of renal cell carcinoma with bone metastases: Experience from a large cancer centre
22. Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer
23. Activity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3: European Organization for Research and Treatment of Cancer (EORTC) phase II trial 90101 ‘CREATE’
24. HSD117 Healthcare Resources Utilization (HCRU) and Exploration of the Patient Journey through Claims Database: An Application on Advanced Renal Cell Carcinoma (ARCC) Patients in France
25. Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone
26. Recommandations en onco-urologie 2016-2018 du CCAFU : Cancer du rein
27. Vinflunine–gemcitabine versus vinflunine–carboplatin as first-line chemotherapy in cisplatin-unfit patients with advanced urothelial carcinoma: results of an international randomized phase II trial (JASINT1)
28. Hypertension and angiotensin system inhibitors: impact on outcome in sunitinib-treated patients for metastatic renal cell carcinoma
29. 184P Elevated baseline circulating IL-8 is associated with increased expression of the IMmotion myeloid gene signature (GS) in metastatic clear cell renal cell carcinoma (mRCC) patients (pts) treated with nivolumab (nivo) within the NIVOREN GETUG-AFU 26 study
30. 23P Circulating immune cells and activity of immune checkpoint inhibitors in metastatic renal cell carcinoma
31. PD-L1 expression in nonclear-cell renal cell carcinoma
32. Triple combination of bevacizumab, gemcitabine and platinum salt in metastatic collecting duct carcinoma
33. Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100)
34. Benefit of adjuvant trastuzumab-based chemotherapy in T1ab node-negative HER2-overexpressing breast carcinomas: a multicenter retrospective series
35. How to select amongst available options for the treatment of advanced RCC?
36. Novel and bone-targeted agents for CRPC
37. Incidence and management of mTOR inhibitor-associated pneumonitis in patients with metastatic renal cell carcinoma
38. LBA75 Prospective randomised phase-II trial of ipilimumab/nivolumab versus standard of care in non-clear cell renal cell cancer: Results of the SUNNIFORECAST trial
39. LBA74 Final analysis of the phase III LITESPARK-005 study of belzutifan versus everolimus in participants (pts) with previously treated advanced clear cell renal cell carcinoma (ccRCC)
40. LBA73 Tivozanib–nivolumab vs tivozanib monotherapy in patients with renal cell carcinoma (RCC) following 1 or 2 prior therapies including an immune checkpoint inhibitor (ICI): Results of the phase III TiNivo-2 study
41. 1717TiP CARE1 pragmatic clinical trial: First line randomised study platform to optimize treatment in patients with metastatic renal cell carcinoma
42. 1698P Avelumab + axitinib (Ave + Axi) vs sunitinib (Sun) in advanced renal cell carcinoma (aRCC): Final analysis of patient (pt)-reported outcomes (PROs) and quality-adjusted time without symptoms or toxicity (Q-TWiST)
43. 1693P CaboPoint: Final results from a phase II study of cabozantinib after checkpoint inhibitor (CPI) combinations in patients with advanced renal cell carcinoma (aRCC)
44. 1691P Subcutaneous nivolumab (NIVO SC) vs intravenous nivolumab (NIVO IV) in patients (pts) with previously treated advanced or metastatic clear cell renal cell carcinoma (ccRCC): Updated efficacy and safety results from CheckMate 67T
45. 156P Microbiota-related multiomics to assess the clinical relevance of antibiotics (ATB) in immunotherapy (ICI)
46. How to select targeted therapy in renal cell cancer
47. Nouvelles thérapeutiques du cancer de la prostate métastatique résistant à la castration
48. Bamlanivimab + etesevimab therapy induces SARS-CoV-2 immune escape mutations and secondary clinical deterioration in COVID-19 patients with B-cell malignancies
49. Severe COVID-19 in patients with hematological cancers presenting with viremia
50. Erratum to ‘Efficacy and correlative analyses of avelumab plus axitinib versus sunitinib in sarcomatoid renal cell carcinoma: post hoc analysis of a randomized clinical trial’: [ESMO Open Volume 6, Issue 3, June 2021, 100101]
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.